• About Amgen
  • Science
  • Corporate Giving
  • Site Map
  • Search
  • Privacy & Terms
  • Contact Us
Amgen
  • Patients
  • Medical Professionals
  • Partners
  • Investors
  • Careers
  • Media
  • print
  • mail
  • Home
  • Media
  • Press Releases

  • Overview
  • Fact Sheets
  • Featured Content
  • Press Releases
  • Abgenix Press Release Archives
  • Tularik Press Release Archives
  • Immunex Press Release Archives
  • Awards & Recognition
  • Media Contacts
  • In the News
Press Release Library
2008   |    2007   |    2006   |    2005   |    2004   |    2003   |    2002


Date Title
May. 7, 2008 Amgen Announces Voting Results of Annual Meeting of Stockholders
May. 6, 2008 Amgen to Participate in CHMP Oncology Scientific Advisory Group Meeting in May
May. 1, 2008 Amgen to Participate in Dermatologic and Ophthalmic Drugs Advisory Committee Meeting in June
Apr. 30, 2008 Amgen CFO Bob Bradway to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Apr. 24, 2008 Amgen's First Quarter 2008 Adjusted Earnings Per Share Increased 4 percent to $1.12
Apr. 16, 2008 Amgen Announces Webcast of 2008 First Quarter Financial Results
Apr. 15, 2008 Amgen Presents Preclinical and Clinical Data from Oncology Programs
Apr. 14, 2008 Amgen Scientist Visits Los Angeles Classroom During Teach For America Week
Apr. 13, 2008 Early Data on Amgen's Anti-Angiogenesis Pipeline Molecules Suggest Biologic Activity Across Tumor Types
Apr. 11, 2008 Amgen-Teach for America Summit to Focus on Strategies for Advancing Math and Science Education
Apr. 8, 2008 Amgen Statement on Romiplostim PDUFA Date
Apr. 3, 2008 Amgen's Oncology Pipeline Data Highlighted at Upcoming Scientific Meeting
Apr. 3, 2008 National Kidney Foundation Introduces Plan to Track Patients in National Screening Program
Apr. 2, 2008 Pivotal Phase 3 Data Show Denosumab Increased Bone Density at Multiple Skeletal Sites in Early and Later Stage Postmenopausal Women
Mar. 17, 2008 Amgen and Wyeth Announce Updates to U.S. Prescribing Information for Enbrel(R)
Mar. 14, 2008 Amgen to Present at the 28th Annual Cowen Healthcare Conference and the 11th Annual Lehman Brothers Global Healthcare Conference
Mar. 13, 2008 Amgen to Discuss Benefits and Risks of ESA Treatment for Cancer Patients with Anemia Due to Chemotherapy at FDA ODAC Meeting
Mar. 12, 2008 Amgen Statement on Successful Outcome of Romiplostim Panel Meeting
Mar. 12, 2008 Amgen to Discuss Romiplostim Application at FDA ODAC Meeting
Mar. 7, 2008 Amgen Announces Update to U.S. Prescribing Information for Aranesp(R) and EPOGEN(R)
Mar. 5, 2008 Kyowa Hakko and Amgen Enter Licensing Agreement for Anti-CCR4 Humanized Monoclonal Antibody
Mar. 5, 2008 The Colon Cancer Alliance Teams up with Joan Lunden for Amgen Sponsored Workshop Series Designed to Provide Support to Patients and Caregivers
Mar. 5, 2008 EU Commission Approves Updated Prescribing Information for Aranesp(R)
Mar. 4, 2008 KRAS Biomarker Analysis from Pivotal Vectibix(TM) Trial Published
Feb. 4, 2008 Amgen and Takeda Announce Exclusive Collaboration in Japan on up to 13 Amgen Clinical Candidates
Feb. 1, 2008 New Findings Show Enbrel(R) (etanercept) Significantly Reduced Levels of C-Reactive Protein, a Marker of Inflammation, in Patients with Moderate to Severe Plaque Psoriasis
Jan. 31, 2008 Pooled Phase 3 Study of Nplate(TM) (Romiplostim) in Adult Patients with Chronic ITP Published in The Lancet
Jan. 28, 2008 Amgen Statement on Aranesp Manuscript in the Journal of Clinical Oncology
Jan. 27, 2008 Interim Safety Data Presented on Vectibix(TM) (Panitumumab) in Combination with Standard Chemotherapy
Jan. 24, 2008 Amgen's Fourth Quarter 2007 Adjusted Earnings Per Share (EPS) Increased 11 Percent to $1.00; Full Year 2007 Adjusted EPS Increased 10 Percent to $4.29
Jan. 24, 2008 Denosumab Osteoporosis Study Met Primary and All Secondary Bone Mineral Density Endpoints in a Head-to-Head Comparison with Weekly Alendronate (FOSAMAX(R))
Jan. 24, 2008 KRAS Gene Status May Impact Vectibix(TM) (Panitumumab) Efficacy and Patient Reported Outcomes in Advanced Colorectal Cancer Patients
Jan. 17, 2008 Amgen Commences Registered Exchange Offer for Its Senior Floating Rate Notes Due 2008, 5.85 Percent Senior Notes Due 2017 and 6.375 Percent Senior Notes Due 2037
Jan. 16, 2008 New Study Reports Enbrel(R) (Etanercept) Significantly Improved Moderate to Severe Plaque Psoriasis in Children and Adolescents
Jan. 16, 2008 Amgen Announces Webcast of 2007 Fourth Quarter and Full Year Financial Results
Jan. 10, 2008 Breakaway from Cancer Public Service Announcement Spreads Support and Hope
Jan. 8, 2008 Amgen Updates 2007 Adjusted EPS Guidance and Outlines 2008 Expense Outlook at the JP Morgan Healthcare Conference
Jan. 4, 2008 Amgen to Present at the 26th Annual JP Morgan Healthcare Conference
footer